| Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma AG Duffy, SV Ulahannan, O Makorova-Rusher, O Rahma, H Wedemeyer, ... Journal of hepatology 66 (3), 545-551, 2017 | 766 | 2017 |
| Population attributable fractions of risk factors for hepatocellular carcinoma in the United States OV Makarova‐Rusher, SF Altekruse, TS McNeel, S Ulahannan, AG Duffy, ... Cancer 122 (11), 1757-1765, 2016 | 305 | 2016 |
| Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer SV Ulahannan, JR Brahmer Cancer investigation 29 (4), 325-337, 2011 | 98 | 2011 |
| Earlier presentation and application of curative treatments in hepatocellular carcinoma SV Ulahannan, AG Duffy, TS McNeel, JK Kish, LA Dickie, OE Rahma, ... Hepatology 60 (5), 1637-1644, 2014 | 97 | 2014 |
| Phase I and preliminary phase II study of TRC105 in combination with sorafenib in hepatocellular carcinoma AG Duffy, C Ma, SV Ulahannan, OE Rahma, O Makarova-Rusher, L Cao, ... Clinical Cancer Research 23 (16), 4633-4641, 2017 | 83 | 2017 |
| Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with … AG Duffy, OV Makarova‐Rusher, SV Ulahannan, OE Rahma, S Fioravanti, ... International journal of cancer 139 (7), 1648-1657, 2016 | 75 | 2016 |
| A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial SI Ou, M Koczywas, S Ulahannan, P Janne, J Pacheco, H Burris, ... Journal of Thoracic Oncology 15 (2), S15-S16, 2020 | 61 | 2020 |
| Pancreatic Squamous Cell Carcinoma: A Population-based Study of Epidemiology, Clinicopathologic Characteristics and Outcomes O Makarova-Rusher, S Ulahannan, T Greten, A Duffy pancreas, 2016 | 50 | 2016 |
| A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib AG Duffy, SV Ulahannan, L Cao, OE Rahma, OV Makarova-Rusher, ... United European Gastroenterology Journal 3 (5), 453-461, 2015 | 49 | 2015 |
| A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms JJ Luke, MR Patel, EP Hamilton, B Chmielowski, SV Ulahannan, ... J Clin Oncol 38 (15), 3004-3004, 2020 | 47 | 2020 |
| A phase 1a/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors NB Mettu, SV Ulahannan, JC Bendell, I Garrido-Laguna, JH Strickler, ... Clinical Cancer Research 28 (5), 882-892, 2022 | 42 | 2022 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 34 | 2023 |
| First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb),±cemiplimab in patients (pts) with advanced malignancies. KP Papadopoulos, NJ Lakhani, ML Johnson, H Park, D Wang, TA Yap, ... Journal of Clinical Oncology 37 (15_suppl), 2508-2508, 2019 | 32 | 2019 |
| Phase ia/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors EA Lim, JC Bendell, GS Falchook, TM Bauer, CG Drake, JH Choe, ... Clinical Cancer Research 28 (22), 4871-4884, 2022 | 31 | 2022 |
| Avelumab plus talazoparib in patients with BRCA1/2-or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial AM Schram, N Colombo, E Arrowsmith, V Narayan, K Yonemori, ... JAMA oncology 9 (1), 29-39, 2023 | 26 | 2023 |
| Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or … AG Duffy, OV Makarova-Rusher, D Pratt, DE Kleiner, S Fioravanti, ... Journal of Clinical Oncology 34 (4_suppl), 270-270, 2016 | 26 | 2016 |
| Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A DVT Catenacci, YK Kang, HH Yoon, BY Shim, ST Kim, DY Oh, AI Spira, ... ESMO open 7 (5), 100563, 2022 | 23 | 2022 |
| First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma … JSZ Wang, S De Vita, JL Karlix, C Cook, GM Littlewood, MM Hattersley, ... Journal of Clinical Oncology 37 (15_suppl), 3085-3085, 2019 | 23 | 2019 |
| Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2–advanced breast cancer: phase 1 results M Maglakelidze, I Bulat, D Ryspayeva, BM Krastev, M Gogiladze, ... J Clin Oncol 39 (15_suppl), 1063, 2021 | 22 | 2021 |
| Preclinical evaluation and phase Ib study of prexasertib, a CHK1 inhibitor, and samotolisib (LY3023414), a dual PI3K/mTOR inhibitor DS Hong, KN Moore, JC Bendell, DD Karp, JS Wang, SV Ulahannan, ... Clinical Cancer Research 27 (7), 1864-1874, 2021 | 22 | 2021 |
Tim GretenNational Cancer InstituteGeverifieerd e-mailadres voor nih.gov
